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Preoperative radiotherapy combined with 5 days per week
capecitabine chemotherapy in locally advanced rectal cancer
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There is increasing evidence supporting the use of preoperative chemoradiotherapy in patients with locally advanced rectal cancer in
an attempt to facilitate complete surgical resection with clear margins. We describe our experience of using a 5-day per week regime
of preoperative capecitabine chemoradiotherapy. Between November 2004 and September 2006, 70 patients with MRI-defined
locally advanced rectal cancer were selected for treatment. Capecitabine was given at a dose of 900 mg m2 for 5 days per week
combined with 45 Gy of radiotherapy in 25 doses. This regime was well tolerated with 89% of our patients receiving the full dose of
chemotherapy and 96% receiving the full dose of radiotherapy. Ninety-three per cent proceeded to macroscopically complete
surgical resection. The pathological complete response rate was 9.2% with a node-negative rate of 66%. A negative circumferential
margin was achieved by 79% of the patients who underwent resection. Compared to studies using a 7-day per week capecitabine
schedule, our results show increased compliance and less dose reductions with comparable pathological outcome.
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There is clear evidence from two systematic reviews that adjuvant
radiotherapy reduces the risk of local recurrence in patients with
resectable rectal cancer (Camma et al, 2000; Colorectal Cancer
Collaborative, 2001). The greatest benefit is seen when preopera-
tive radiotherapy is used with a biologically equivalent dose of
430 Gy. Further clinical trials were required to assess the benefit
of adding concurrent chemotherapy to preoperative radiotherapy.
The recent publication of two phase III trials confirms that
preoperative concurrent chemoradiation (CRT) is superior to
long-course radiotherapy alone in patients with T3/4 or node-
positive resectable rectal cancer. The EORTC 22921 (Bosset et al,
2005) and FFCD 9203 (Gerard et al, 2006) trials compared
intravenous 5-fluorouracil (5FU) and leucovorin (LV) given during
the first and fifth weeks of radiotherapy with radiotherapy alone
(dose of RT was 45 Gy in 25 fractions in both arms of the studies).
Both trials demonstrated a reduction in the rates of local
recurrence at 5 years from 17% with radiotherapy alone to 8–9%
with preoperative CRT, but neither trial showed any difference in
overall survival. A further recent phase III trial has demonstrated
that preoperative 5FU CRT is superior to post-operative CRT with
a significant reduction in local recurrence from 12 to 6% as well as
a significant reduction in both acute and long-term toxicity (Sauer
et al, 2004). This evidence will clearly result in an increasing use of
fluoropyrimidine-based CRT.
Intravenous 5FU-based chemoradiation presents many logistical
challenges. Continuous infusion of 5FU requires the insertion of a
central venous line with its attendant risks of thrombosis and
infection as well as the inconvenience of a portable infusion pump.
The use of the bolus 5FU/LV regimen used in the EORTC and
FFCD trials requires 10 daily visits to the chemotherapy day unit,
with associated waiting time, the need for repeat venepuncture and
the need for close coordination of the timing of the delivery of
chemotherapy and radiation.
Capecitabine is an oral, tumour-activated fluoropyrimidine.
Two large randomised phase III trials have compared capecitabine
against low-dose LV and 5FU (Mayo regimen) in patients with
metastatic colorectal cancer with no difference in time to
progression or overall survival (Van Cutsem et al, 2004). In
addition, two randomised, controlled trials have shown at least
equivalent disease-free survival with the use of an oral fluropyr-
imidine when compared with low-dose LV and 5FU as post-
operative adjuvant therapy for stages II and III colon cancer
(Wolmark et al, 2004; Twelves et al, 2005). Furthermore, the use of
oral capecitabine has been supported by recent NICE guidance on
the management of colon cancer in both the metastatic and
adjuvant settings (NICE, 2003, 2006). These results support the
rationale for developing oral fluoropyrimidine-based chemoradia-
tion.
Two formal dose-finding studies have been performed that
escalate the dose of capecitabine when added to a fixed dose of
pelvic radiation in rectal cancer. Dunst et al (2002) reported a
recommended dose of 825 mg m2 7 days per week for phase II
study, whereas Ngan et al (2004) recommended 900 mg m2 5 days
per week. We decided to further evaluate the use of the latter
regimen.
In the United Kingdom, high-resolution pelvic MRI is increas-
ingly used to determine the relationship of the primary tumour to
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the potential margins of surgical resection. This correlation was
reported by Brown et al (2003) in a single-centre experience and
has been described by other centres (Blomqvist et al, 1999; Beets-
Tan et al, 2001; Bissett et al, 2001; Botterill et al, 2001). A large
international prospective multicentre study (MERCURY trial) has
demonstrated that the extent of tumour seen on the preoperative
MRI scan is equivalent to that seen in the resected pathological
specimen in patients who undergo initial surgery with or without
short-course preoperative radiotherapy (MERCURY Study Group,
2006). These findings led us to adopt the routine use of pelvic MRI
in determining the selection of patients for preoperative radio-
therapy and chemoradiation (Sasapu et al, 2006). Using pelvic
MRI, patients are selected for preoperative CRT if the margins of
resection are considered to be at risk. The main aim of treating
such patients is to achieve a macroscopic complete resection with
histologically confirmed clear (uninvolved) resection margins.
PATIENTS AND METHODS
Between November 2004 and September 2006, patients with locally
advanced rectal cancer were selected for preoperative capecitabine
CRT on clinical and radiological findings. CRT was indicated if (i)
the mesorectal fascia (MRF) was threatened (macroscopic tumour
located within 2 mm of the MRF on the MRI), (ii) the MRF was
involved (up to or beyond the MRF on the MRI), or (iii) there was
T3 or T4 tumour with distal extent within 5 cm of the anal verge.
The patient was considered suitable for capecitabine therapy, if
their glomerular filtration rate was 450 ml min1 and they were
able to comply with self-medication.
Radiotherapy
Clinical examination determined the distal extent of the primary
tumour, and the pelvic MR images were used to determine the
gross tumour volume, which is outlined on individual slices of a
computed tomography (CT) planning scan. Margins were added to
the gross tumour volume to create the planning target volume
(3 cm lateral and 3– 5 cm superior, 2 cm anterior and 2 –3 cm
inferior). The posterior border was always located at the posterior
border of the body of the sacrum. Unless contraindicated, patients
were treated in the prone position with a full bladder using a 3- or
4-field technique. Small bowel imaging was achieved using oral
gastrograffin (20 ml in 1000 ml water) 45 minutes prior to the
planning CT scan. A total dose of 45 Gy in 25 fractions over 5
weeks was prescribed to the ICRU (intersection) point and this was
delivered using 3- or 4-radiation beams with the use of multileaf
collimation.
Chemotherapy
Capecitabine was prescribed at a dose of 900 mg m2 twice daily
for 5 days per week for 5 weeks. The patients were advised to take
the prescribed capecitabine dose at 0900 and 2100 hours on the
days they received radiotherapy. Routine haematological tests (full
blood count and urea and electrolytes) were carried out before
CRT commenced and again at week 3. The patients were
monitored weekly for toxicities. In the presence of grade III/IV
acute toxicity, the dose of capecitabine was reduced or if necessary
discontinued.
Surgery and histopathology
Prior to surgery, patients were reassessed 4–6 weeks after
completion of CRT by repeat pelvic MRI±thoracoabdominal CT.
The recommended timing to perform surgery was 6–8 weeks
following CRT.
The resected specimen was examined using the methods
described by Quirke et al (1986). The tumour was not opened
and was fixed in formalin. The circumferential margin was then
stained with Indian ink and axial thin slices were made. The
specimen was examined macroscopically and blocks were taken
from all suspicious areas. Pathological complete response (pCR)
was defined by the complete absence of tumour cells from the
entire specimen. The circumferential resection margin (CRM) was
routinely evaluated and considered to be involved if there was
evidence of any microscopic tumour p1 mm from the painted
CRM edge.
RESULTS
Between November 2004 and September 2006, 70 patients from the
Yorkshire Cancer Network (45 men and 25 women) have been
selected for capecitabine CRT. The tumour characteristics at
preoperative staging are shown in Table 1. Thirty-two patients
(46%) had tumours with a distal limit o5 cm from the anal verge.
Thirty-four patients (49%) had tumours 45 cm from the anal
verge (31 patients 5–10 cm and 3 patients 410 cm) and there were
four patients, where the distance was not stated. Of the 34 patients
with mid to upper rectal tumours (45 cm from anal verge), 22 had
a threatened MRF (65%) and 12 had tumour involving the MRF
(35%).
Acute toxicity and compliance
All 70 patients have completed their treatment and were assessed
for capecitabine CRT toxicity. Sixty-two (88.6%) patients received
the full dose of capecitabine without suffering significant grade
3 or 4 toxicities. Three (4.3%) patients had to discontinue
capecitabine due to acute toxicities. One patient with a known
cardiac history developed unstable angina and was admitted to
Table 1 Tumour characteristics on presentation and the toxicities
observed during capecitabine CRT
Number of patients
Tumour characteristics Total (%) Male Female
Number of patients 70 45 25
Distance from anal verge (cm)
0–5 32 (46) 19 13
5–10 31 (44) 22 9
10–15 3 (4) 3 0
Unknown 4 (6) 1 3
Pre-op staging (MRI)
T2 3 (4) 1 2
T3 52 (74) 34 18
T4 11 (16) 8 3
Not stated 4 (6) 2 2
Compliance with treatment
Capecitabine therapy
Full dose 62 (89) 44 18
Dose reduction 5 (7) 0 5
Did not complete course 3 (4) 1 2
Radiotherapy
Full dose 67a (96) 43 24a
Did not complete course 3 (4) 2 1
CRT¼ concurrent chemoradiation; MRI¼magnetic resonance imaging. aTwo
patients received the full dose of radiotherapy but required a break from treatment
of between 2 and 5 days due to capecitabine toxicity.
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coronary care unit; one patient had pre-existing ulcerative colitis
and was operated on acutely for large bowel distension; one patient
developed severe abdominal pain and diarrhoea. It is not possible
to determine the relative contribution of the capecitabine and
radiotherapy in the cause of the abdominal toxicity.
Five (7.1%) patients required dose reductions in capecitabine.
One patient had a low glomerular filtration rate at commencement
of therapy and received an elective 20% dose reduction throughout
treatment; one patient suffered from a deterioration in renal
function at week 3 (creatinine 129 from 89mmol l1 prior to
treatment commencing), and the dose was omitted for a week and
then started at a 20% reduction; three patients suffered grade
3 diarrhoea and had dose reductions of between 10 and 25%.
Sixty-seven (96%) patients received the full 45-Gy dose of
radiotherapy. Out of the three patients (4%) who failed to receive
the full dose, one patient was considered too unwell to receive his
last dose (received 43.2 Gy in total), and two patients were
admitted with abdominal pain (described above) having received
41.4 and 37.8 Gy, respectively. Two other patients required a break
in RT (2–5 days) due to capecitabine toxicity.
Surgical resection
Complete macroscopic resection was performed in 65 of the 70
patients (93%) who received capecitabine CRT. Resection was not
performed in five patients. Two patients developed inoperable lung
metastases identified on the CT scan performed 6 weeks after
completion of CRT; one patient died from disease progression
shortly after CRT had finished; one patient developed inoperable
disease with sacral involvement; one patient was not resected
because of an unacceptably high risk of perioperative mortality
due to pre-existing cardiorespiratory comorbidities.
One patient had an emergency resection 9 days after completing
CRT for large bowel obstruction. The timing of elective surgical
resection varied from weeks 4 to 23 post-CRT, with a median of 8
weeks (interquartile range: 7– 9.5 weeks).
Histopathology
The histopathological results are summarised in Table 2. Of the
65 patients who underwent resection, 6 patients (9.2%) had a
complete pathological response (pCR or ypT0N0). One further
patient had complete regression of the primary tumour but had 1
out of 22 positive lymph nodes (ypT0N1). There were 21 (32.3%)
patients with ypT0 – 2 tumours. Out of the 64 patients, where
preoperative MRI staging was available, 26 patients (41%) were
downstaged by CRT and in 4 patients (6%) disease progressed.
Twenty-two (33.8%) patients had node-positive disease. The
median number of nodes examined was 13.2 (interquartile range:
7–18).
The number of resections achieving a negative CRM was high
with 51 (79.7%) specimens having an uninvolved CRM (one
specimen could not be evaluated due to surgical trauma). Table 3
shows the CRM status by operation performed and tumour
location. Circumferential resection margin involvement was seen
in 15.2% of anterior resections (5 out of 33) compared to 7 out of
26 abdominoperineal excision resection specimens (26.9%). The
rate of CRM involvement for tumours within 5 cm of the anal verge
was 29% (9 out of 31), whereas it was 13.3% (4 out of 30) in higher
tumours (45 cm).
DISCUSSION
This series of patients, receiving a 5-day per week schedule of
capecitabine and radiotherapy, shows similar efficacy and high
compliance compared to intravenous 5FU/LV regimes. In this
series, 67 (96%) patients received the full 45 Gy dose of radio-
therapy and this is comparable to the large EORTC (96%) and
FFCD (97.1%) trials. Sixty-two patients (89%) received the
protocol dose of capecitabine compared to 83.7% receiving the
correct dose of i.v. 5FU/LV in the EORTC and 78.1% in the FFCD
trials. In our study, a further 7% of patients completed the course
of capecitabine with a 10–25% dose reduction.
At the time of writing, there were two published phase II trials
of capecitabine CRT (De Paoli, 2006; Krishnan et al, 2006) and a
further study comparing capecitabine CRT to 5FU/LV (Kim et al,
2007), and all three used the 825 mg m2 continuous daily
schedule. In these studies, the number of patients receiving the
full dose of capecitabine was much lower compared to our 5-day
schedule. The study by De Paoli showed that 72% of patients
received the full dose, whereas in the study by Krishnan, 11 out of
the 54 (20%) patients received a dose reduction, and 11 out of the
54 (20%) patients had treatment stopped before completion (it is
not clear whether or not these were the same 11 patients). The
study by Kim et al (2007) published no data on the number of
patients receiving dose reductions but quoted a 99.3% chemother-
apy completion rate. Without detailed toxicity data, it is difficult to
compare compliance between the 5- and 7-day regimes, but the
available evidence suggests that more dose modifications are
required using a 7-day schedule.
In our study, 93% of the patients who received capecitabine CRT
went on to have a complete macroscopic resection, although there
is some variation in the timing of surgery. It was recommended
that surgery took place 6–8 weeks following completion of CRT,
although most colorectal multi-disciplinary teams (MDTs) accept
that the optimised timing of surgery is not defined. We feel that the
quoted interquartile range of 7.5–9 weeks demonstrates acceptable
Table 2 Pathological stages of the patients who underwent surgical
resectiona
ypT stage ypN stage
Pre-op MRI ypT0 ypT1 ypT2 ypT3 ypT4 ypN0 ypN+
Not stated 1 1 1 2 1
T2 1 1 1 1
T3 5 1 10 30 4 31 19
T4 1 1 7 1 9 1
Total (%) 7 (11%) 1 (1.5%) 13 (20%) 38 (59%) 6 (9%) 43 (66%) 22 (34%)
MRI¼magnetic resonance imaging. aThe circumferential resection margin was not
assessed on one specimen due to surgical trauma.
Table 3 The rates of CRM positivity in different groups of patients
CRM status CRM-positive
rate
Total Positive Negative (%)
Whole populationa 64 13 51 20.3
Operation
Anterior resection 33 5 28 15.2
Abdominoperineal resection 26 7 19 26.9
Pelvic exenteration 5 1 4 20.0
Distance from anal vergeb (cm)
0–5 31 9 22 29.0
45 30 4 26 13.3
CRM¼ circumferential resection margin. aOne patient who had an abdominoperineal
resection and a tumour 4 cm from the anal verge was not assessed due to trauma to
the specimen. bThree patients with unknown tumour location.
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compliance with our recommendations. Over 50% of the patients
had surgery 6 –8 weeks, and 79% had surgery 6– 10 weeks
following completion of CRT. The delays in surgery appear to be
simply due to the challenge of finding available operating time.
There is no evidence to suggest that surgery was delayed to allow
more time for tumour regression.
There was only one patient who had a resection before 4 weeks
due to developing abdominal signs and symptoms requiring
urgent surgery. Of the remaining 64 patients, 30 had surgery 48
weeks and 34 had surgery p8 weeks. The pathological ypT0-2
stage was 40 and 23%, the node-negative rate was 71 and 60% and
the CRM-negative rate was 86 and 73%, respectively. An APER was
performed in 13 out of the 35 (37%) patients who underwent
surgery p8 weeks and 14 out of the 30 (47%) patients who
underwent surgery 48 weeks after completion of CRT. The
numbers are too small to allow formal statistical comparison.
It is important to emphasise that this group of patients were
defined by MRI as locally advanced, where the margin of excision
was considered at risk. Of the 66 patients classified preoperatively,
11 (17%) presented with T4 and 52 (79%) presented with T3
disease on pelvic MRI. The tumour was directly threatening or
involving the resection margins in 61 cases (88%). Due to this
caseload, we may expect to see lower rates of downstaging
compared to other studies. The pCR rate in this study was 9.2%
(EORTC 13.7%, FFCD 12.1%), with an additional patient having a
complete response of the primary tumour but positive nodes (1 out
of 22 nodes were positive). The rate of ypT0 – 2 tumours was 32.3%
with 41% of patients downstaged, according to their diagnostic
MRI. Due to the advanced nature of presentation one would expect
a high rate of lymph node involvement, so a node-negative rate of
66.2% is also encouraging.
The number of resections achieving a negative CRM status is
high (79.7%). These results compare favourably with pooled data
from 677 patients treated in six UK centres with 5FU/LV pre-op
CRT, where the pCR rate was 13%, and 388 (70%) of resected
patients achieved an uninvolved CRM (Sebag-Montefiore et al,
2005b). The intention-to-treat analysis (see Figure 1) shows that we
achieved a negative CRM in 51 out of the 70 cases (73%). This
compares favourably to the 65% CRM-negative rate reported in a
study using 5FU/LV in patients presenting with similar advanced
disease (Mawdsley et al, 2005). The ITT pCR rate (i.e., from the
total number of patients selected for CRT) was similar in both
studies (8.6% in our study vs 10% in the study by Mawdsley).
The value of using the degree of response to CRT (either pCR or
rate of downstaging) as an end point for assessing efficacy is
debatable. Circumferential resection margin status predicts for
local recurrence and overall survival (Birbeck et al, 2002; Wibe
et al, 2002). However, CRM status is rarely reported. In a review of
215 phase II and III studies of radiotherapy and chemoradiotherapy
in rectal cancer, only 14 presented data on the negative CRM rate
(Glynne-Jones et al, 2006).
Table 3 shows the CRM status for different operations and
different levels of tumour. There is a higher rate of CRM
involvement in patients with low tumours and this is seen for
both tumour position (o5 cm from the anal verge – 29%) and by
operation performed (abdominoperineal resection – 25.9%). The
overall rate of CRM involvement (20.3%) remains high and
emphasises the need to improve treatment either by intensifying
the preoperative CRT or by improving surgical techniques.
The argument for intensifying CRT is supported by a systematic
analysis of phase II and III trials in preoperative CRT in rectal
cancer that suggested that the use of a second chemotherapeutic
agent increased the pCR rate (P¼ 0.001). This has been supported
by several large phase II trials (Glynne-Jones et al, 2005, 2007;
Sebag-Montefiore et al, 2005a; Gollins et al, 2006).
Abdominoperineal resections are associated with increased
CRM involvement, increased intraoperative tumour perforations
and decreased overall survival (Marr et al, 2005; Nagtegaal et al,
2005). An alternative approach to the perineal element of the
abdominoperineal resection, designed to minimise circumferential
involvement, has been proposed with promising initial results
(Holm et al, 2007).
This is the only large study of a 5-day per week capecitabine
schedule. This series of patients shows that this regimen has
excellent compliance and tolerance, with similar efficacy to other
studies published and could be used in future phase III trials,
looking at the addition of a second chemotherapy drug or
antibody. It would be particularly useful to have a 5-day per week
capecitabine CRT schedule if the novel arm in a phase III trial used
a similar schedule (e.g., the CORE regimen using oxaliplatin
50 mg m2 once weekly and capecitabine 825 mg m2 b.d. 5 days
per week, both for 5 weeks).
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Patients selected for
capecitabine CRT 
70 
Patients achieving 
macroscopic resection
65 (93%) 
CRM positive* 
13 (19%) 
CRM negative* 
51 (73%) 
Developed M1
disease after CRT
2 
Inoperable tumour after
CRT 
1 
Died before surgery due
to disease progression
1 No operation due to 
co-morbidities 
1 
Figure 1 Outcome of the 70 patients selected for capecitabine chemoradiotherapy (*one specimen was not assessed for CRM status due to surgical
trauma).
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